» Articles » PMID: 18671640

Role of Galectin-1 in Migration and Invasion of Human Glioblastoma Multiforme Cell Lines

Overview
Journal J Neurosurg
Specialty Neurosurgery
Date 2008 Aug 2
PMID 18671640
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Object: Galectin-1 is highly expressed in motile cell lines. The authors investigated whether galectin-1 actually modulates the migration and invasion of human glioblastoma multiforme (GBM) cell lines, and whether its expression with respect to invasion and prognosis is attributable to certain glioma subgroups.

Methods: In the human GBM cell lines U343MG-A, U87MG, and U87MG-10', the RNA differential display was evaluated using Genefishing technology. The results were validated by reverse transcription polymerase chain reaction and Northern blot analysis to detect possible genetic changes as the determining factors for the motility of the malignant glioma. The migration and invasion abilities were investigated in human GBM cell lines and galectin-1 transfectant using an in vitro brain slice invasion model and a simple scratch technique. The morphological and cytoskeletal (such as the development of actin and vimentin) changes were examined under light and confocal microscopy. Galectin-1 expression was assessed on immunohistochemical tests and Western blot analysis.

Results: Endogenous galectin-1 expression in the human GBM cell lines was statistically correlated with migratory abilities and invasiveness. The U87-G-AS cells became more round than the U87MG cells and lacked lamellipodia. On immunohistochemical staining, galectin-1 expression was increased in higher-grade glioma subgroups (p = 0.027).

Conclusions: Diffuse gliomas demonstrated higher expression levels than pilocytic astrocytoma in the Western blot. Galectin-1 appears to modulate migration and invasion in human glioma cell lines and may play a role in tumor progression and invasiveness in human gliomas.

Citing Articles

Galectin inhibitors and nanoparticles as a novel therapeutic strategy for glioblastoma multiforme.

Elliott Jr W, Tsung A, Guda M, Velpula K Am J Cancer Res. 2024; 14(2):774-795.

PMID: 38455415 PMC: 10915327.


Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implications.

Yaylim I, Aru M, Farooqi A, Hakan M, Buttari B, Arese M Cancer Drug Resist. 2024; 7:8.

PMID: 38434765 PMC: 10905161. DOI: 10.20517/cdr.2023.79.


Distinct Specialized Center of Excellence, the Story of Hwasun Neurosurgery at Chonnam National University Hwasun Hospital.

Jung S, Kim I, Moon K, Jung T, Jang W, Kim Y Brain Tumor Res Treat. 2023; 11(2):94-102.

PMID: 37151151 PMC: 10172013. DOI: 10.14791/btrt.2023.0005.


Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy.

Lau L, Mohammed N, Dimitroff C Int J Mol Sci. 2022; 23(24).

PMID: 36555198 PMC: 9778980. DOI: 10.3390/ijms232415554.


Galectin-1 activates carbonic anhydrase IX and modulates glioma metabolism.

Guda M, Tsung A, Asuthkar S, Velpula K Cell Death Dis. 2022; 13(6):574.

PMID: 35773253 PMC: 9247167. DOI: 10.1038/s41419-022-05024-z.